Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.55 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257619 | 0.90 | KIF11 (0.49) | KIF11KDM1AKCNH2KDM1BIDO1 | |
| SCHEMBL30285974 | 0.88 | ALDH1A1 (0.54) | KIF11IDO1CYP11B1CYP11B2ESR1 | |
| SCHEMBL1042606 | 0.88 | ALDH1A1 (0.54) | KIF11IDO1CYP11B1CYP11B2ESR1 | |
| SCHEMBL2741575 | 0.86 | KIF11 (0.46) | KIF11KDM1AKCNH2KDM1BIDO1 | |
| SCHEMBL2852129 | 0.86 | KIF11 (0.55) | KIF11ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL31528309 | 0.84 | KIF11 (0.45) | KIF11KDM1AKCNH2KDM1BIDO1 | |
| SCHEMBL430474 | 0.84 | CYP17A1 (0.50) | KIF11IDO1CYP11B1CYP11B2LMNA | |
| SCHEMBL851174 | 0.84 | TAAR1 (0.53) | KIF11CYP11B1CYP11B2ESR2HSD17B1 | |
| SCHEMBL999759 | 0.82 | CYP11B1 (0.44) | KIF11IDO1CYP11B1CYP11B2 | |
| SCHEMBL12384880 | 0.81 | RAB9A (0.44) | KIF11IDO1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | INFINITY PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9034849-B2 | Fatty acid amide hydrolase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034849-B2 | Fatty acid amide hydrolase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034849-B2 | Fatty acid amide hydrolase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2531511-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | Infinity Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| WO-2011097233-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097233-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | KIF11 4227/4885KDM1A 494/4885KCNH2 3767/4885 |
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | FAAH, FAAH2, FASN | KIF11 4237/4885KDM1A 551/4885KCNH2 3416/4885 |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | KIF11 4227/4885KDM1A 494/4885KCNH2 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.